PLYMOUTH MEETING, Pa., May 25, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO, and Dr. Michael Sumner, CMO, will present at the 2023 Jefferies Healthcare Conference.
2023 Jefferies Healthcare Conference
Date: Friday, June 9, 2023
Time: 8:00 AM ET
Format: Fireside Chat
During the conference, Dr. Shea and members of INOVIO's management team will conduct one-on-one meetings with registered investors.
A webcast of the presentation will be available on the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx. A replay of the webcast will be available for 90 days after the date of the presentation.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's DNA medicines in development are delivered using its investigational proprietary smart device, CELLECTRA®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson (267) 429-8567 This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors: Thomas Hong (267) 440-4298 This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$4.27 |
Daily Change: | -0.50 -10.48 |
Daily Volume: | 668,368 |
Market Cap: | US$110.720M |
November 14, 2024 November 06, 2024 October 21, 2024 October 01, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB